Chronic diseases require specialized attention to tackle given the high prevalence and mortality rates arising from these conditions. A majority of the US population had at least one chronic condition and more than one-fourth of the population had multiple chronic conditions as of 2018. Roughly 74% of the global deaths were as a result of a patient succumbing to a chronic disease and 41% of all chronic deaths occur prematurely (age of death under 70). Of these deaths, nearly 80% were caused by heart attacks and related complications.

Moreover, the prevalence of these diseases are expected to increase significantly in the near future. For instance, total diabetes patients globally is expected to reach 592 million, accounting for roughly 10% of the projected global population by 2025. The US alone is estimated to account for $1T in expenses related to heart disease management and will have nearly 45% of its population with at least one heart conditions

This topic addresses the developments and advancements in the field of chronic disease management. Over the last few years, there has been some considerable development in diabetes/obesity management with therapeutic innovations from Novo Nordisk and Eli Lilly. Given the advancements in AI, biotech, and pharmaceuticals, there is a wider application of therapeutics to not only manage but attempt to cure these chronic conditions.